Surrozen

Edit info

Founded: 2015

Location: South SF, CA

Employee range: 11 - 50

Clinical stage: Clin1a

Therapy area: Severe alcoholic hepatitis

Drug types: HEP, GI, IMM, OPH, GEN

Lead product: SZN-043

Funding: $50M Jun 2020; $50M Mar 2019; $33M A Feb 2017

Investors: Horizons Ventures, Hartford HealthCare Endowment, NS Investment, The Column Group

surrozen.com

linkedin.com

job board

Business:

Wnt signaling antibodies

Drug notes:

SZN-1326 Clin1a IBD; SZN-413 Clin0 retinopathies; 2 undisclosed programs RD dry eye/Sjogren's, Fuch's dystrophy

About:

Surrozen is discovering and developing new drug candidates to treat injury and disease by targeting the Wnt pathway. The Wnt pathway plays a critical role in development processes, stem cell maintenance and tissue regeneration. Combining their understanding of the Wnt pathway with advanced antibody engineering strategies, Surrozen is designing tissue-specific antibodies that engage the body’s own biological repair mechanisms to regenerate tissue. With pharmaceutical properties, Surrozen’s platform has the potential to overcome many of the current limitations of regenerative medicines.

Bioanalytical Scientist - Part-Time - Contractor

South San Francisco, California|24 days ago

Apply

Exec. Director/Vice President, Clinical Developmen...

South San Francisco, California|37 days ago

Main

Contact: recruit@workinbiotech.com